Zoetis wins FDA approval for Convenia RTU for dogs
The FDA approved Convenia RTU for Dogs, a single-injection antibiotic for bacterial skin infections; Zoetis expects vets to have it in Q1 2027.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Zoetis said the US Food and Drug Administration approved Convenia RTU for Dogs (cefovecin injectable suspension) for treating susceptible bacterial skin infections in dogs. A single dose by a veterinarian can provide up to 14 days of treatment, removing the need for daily oral pills.
According to the company, the product is more concentrated, so the same dose fits into a smaller volume, which makes injections easier for dogs of all sizes. Zoetis expects the drug to be available to veterinarians in the first quarter of 2027.
why it matters
The news is niche: the approval widens Zoetis's veterinary dermatology lineup, but the company did not estimate any financial effect. It is of limited relevance to the broader market.
market impact
ZTS: wider veterinary product line; revenue impact not disclosed
tags
instruments
sources
- Zoetis Receives FDA Approval for Convenia® RTU for Dogs (cefovecin injectable suspension), Helping More Medium and Large Dogs Access Single-Injection Treatment — TradingView, 20 October 2026 at 20:42 UTC
- Zoetis Receives FDA Approval For Convenia® Rtu For Dogs (Cefovecin Injectable Suspension), Helping More Medium And Large Dogs Access Single-Injection Treatment — Reuters, 20 October 2026 at 22:02 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗